HER2+ Breast Cancer | Specialty

The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.

Pyrotinib Plus Metronomic Vinorelbine Is Active in HER2+ Advanced Breast Cancer After Trastuzumab

September 5th 2024

Pyrotinib paired with metronomic vinorelbine was safe and displayed efficacy in HER2-positive advanced breast cancer after prior trastuzumab.

Dr Tolaney on Standard Frontline Treatment Approaches in HER2+ Breast Cancer

August 29th 2024

Sara M. Tolaney, MD, MPH, discusses standard-of-care frontline treatment approaches for patients with HER2-positive breast cancer.

Shortened Trastuzumab Administration Does Not Improve DFS in ERBB2+ Breast Cancer

August 29th 2024

Adjuvant trastuzumab plus concurrent chemotherapy led to inferior DFS outcomes when administered for 9 weeks vs 1 year in ERBB2-positive breast cancer.

Dr Forsyth on the Potential Utility of Intrathecal cDC1s in Leptomeningeal Disease

August 27th 2024

Peter Forsyth, MD, discusses the evaluation of intrathecal dendritic cells for patients with TNBC/HER2-positive leptomeningeal disease.

Dr Waks on Ongoing Research in Residual HER2+ Breast Cancer

August 23rd 2024

Adrienne G. Waks, MD, discusses efforts to improve treatment outcomes for patients with HER2-positive breast cancer with residual disease.

Dr O’Brien on Tucatinib Plus Trastuzumab/Capecitabine for Leptomeningeal Metastases in HER2+ Breast Cancer

August 22nd 2024

Barbara Jane O’Brien, MD, discusses tucatinib plus trastuzumab and capecitabine for leptomeningeal metastases in HER2-positive breast cancer.

Dr Nanda on Treatment De-Escalation in HER2+ Breast Cancer and TNBC

August 22nd 2024

Rita Nanda, MD, discusses efforts to de-escalate adjuvant therapy for patients with select breast cancers who responded to neoadjuvant therapy.

Dr Tolaney on Frontline Treatment Approaches in HER2+ Breast Cancer

August 20th 2024

Sara M. Tolaney, MD, MPH, discusses standard frontline treatment approaches for patients with HER2-positive breast cancer.

EMA Accepts Marketing Application for T-DXd in HER2-Low and -Ultralow Metastatic Breast Cancer

August 19th 2024

The EMA has validated a type II variation application for trastuzumab deruxtecan for select patients with HER2-low or -ultralow metastatic breast cancer.

Dr Waks on Anthracycline- vs Taxane-Based Therapy in HER2+ Breast Cancer

August 13th 2024

Adrienne G. Waks, MD, discusses how neoadjuvant and adjuvant anthracycline- and taxane-based regimens compare with one another in HER2+ breast cancer.

Novel Studies Seek to Optimize HER2+ Breast Cancer Management

August 7th 2024

Sara M. Tolaney, MD, MPH, discusses the use of ADCs in HER2-positive breast cancer and ongoing research in this patient population.

Dr Tolaney on Ongoing Clinical Trials in Early-Stage HER2+ Breast Cancer

August 6th 2024

Sara M. Tolaney, MD, MPH discusses ongoing clinical trials investigating the addition of HER2-directed therapies to existing treatment regimens for HER2-positive breast cancer.

Emerging HER2+ Breast Cancer Research Uses Innovative Combinations of Standard Agents

August 6th 2024

Sara M. Tolaney, MD, MPH, discusses the HER2-positive breast cancer treatment paradigm and how standard agents may be optimized to improve outcomes.

Revisit Every OncLive On Air Episode From July 2024

July 31st 2024

In case you missed any, below is a recap of every OncLive On Air episode that aired in July 2024.

Changes in HER2+ Breast Cancer May Include Tailored Therapy With pCR, Use of T-DXd

July 26th 2024

Adrienne G. Waks, MD, discusses the potential for pCR-guided treatment and highlights therapies for patients with residual disease beyond T-DM1.

Tucatinib Retains its Role in HER2+ Metastatic Breast Cancer, Prompting Questions of T-DXd’s Potential Takeover in the First Line

July 24th 2024

Adrienne G. Waks, MD, details her approach to treatment sequencing in metastatic HER2-positive disease and the potential role of T-DXd in the first line.

Neoadjuvant Therapy Selection: Are Abbreviated Regimens an Option in HER2+ Breast Cancer?

July 23rd 2024

Adrienne G. Waks, MD, parses out recent and upcoming data in HER2+ breast cancer and discusses why abbreviated neoadjuvant regimens are not ready for primetime.

Research Propels Additional Options into the Advanced HER2+ Breast Cancer Armamentarium

July 22nd 2024

Sarah Sammons, MD, discusses the evolving treatment landscape for metastatic HER2-postive breast cancer.

De-Escalation Strategies, Biomarkers Could Refine Treatment Algorithm for Early-Stage HER2+ Breast Cancer

July 20th 2024

Sara M. Tolaney, MD, MPH, discusses the use of HER2-directed therapy in the curative setting for HER2-positive breast cancer.

Dr O'Brien on Breast Cancer Research in Patients With HER2+ Brain Metastases

July 18th 2024

Barbara Jane O’Brien, MD, discusses expanding clinical trial enrollment criteria to include patients with HER2-positive breast cancer brain metastases.